Blood-based molecular biomarkers for Alzheimer’s disease
Abstract A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer’s disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current health system to find and diagnose patients with early AD...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Molecular Brain |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13041-019-0448-1 |